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tical expenditure per capita Δ x2009-2012= -37,6%, x2012= 282 € , rebate from pharma-
ceutical companies Δ x2009-2012= +364,1%, net public pharmaceutical expenditure 
Δ x2009-2012= -42,3%, x2012= 2.88 mil € , net public pharmaceutical expenditure per 
capita Δ x2009-2012= -43%, x2012 = 253 € , net public pharmaceutical expenditure as % 
of GDP Δ x2009-2012= -36,3% and in 2012 they constituted 1,4% GDP. Price changes of 
medicines Δ x2005-2011= -17,8%, Δ x2010-2011= -10,7%. ConClusions: Interventions 
implemented in 2010 had according presented parameters a great impact on effec-
tiveness of Health care and Pharmaceutical sector and this improvement will con-
tinue for a few years more. The betterment of Health care and Pharmaceutical sector 
might help to lower the public debt and recover economic credibility of Greece.
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objeCtives: Hopital’s attractiveness can impact the number of inpatients, and so 
health care expenditures. The objective is to identify parameters related to patients 
or drugs, wich influence the proportion of inpatients not residing in the hospital’s 
region, in order to better understand expensive drug expenditures. Methods: A 
database on expensive inpatient drugs listed on a national formulary was set up, 
with information related to drugs -from National and European Health authori-
ties- and patients -from our university hospital centre’s database (UHC) of the 
Paris region. A censored regression model, Tobit model, was developed in which 
the dependent variable was, for each drug, the ratio of the number of inpatients not 
residing in the Paris region, on the total number of inpatients receiving this drug. 
Explanatory variables were related to drugs and to patients. All statistical tests 
were run in Stata/IC13®. Results: During 2012, 526 091 doses -of the 113 drugs 
list- are administered to 30 499 UHC inpatients. 13% of inpatients come from off 
the Paris region. According to the Tobit model, three variables positively impact the 
ratio (innovative status, percentage of women and Diagnosis Related Group coded 
as severe) and three negatively (orphan designation, percentage of patients over 
65 years old, biological origin). Therapeutic classes and Major Diagnostic Categories 
also impact significantly the ratio according to the statistic class. For instance, 
innovative status, defined by a market authorization granted in the five last years 
and a high level of improvement in actual benefit, improves the ratio of 8.6 points. 
To benefit from the most innovative treatments, patients tend to be cared in UHC’s 
hospitals. ConClusions: This study represents the first step of modelling signifi-
cant determinants of hospital’s attractiveness for patients. It focuses, quite uniquely, 
on patients and drugs factors, and could be extended to other variables.
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objeCtives: Clinical researches are an important tool for the improvement of 
medicine and significant economic value. The aim of this study was to investigate 
the economic impact of clinical researches to the research centers and reimburse-
ment system in Turkey. Methods: Budget of clinical trials were calculated from 
the raw data of the Report of Istanbul Medical Faculty Clinical Researches (ITFKAR) 
between years 2006-2010. In addition, the possible cost of the drugs that were used 
in the clinical researches for SGK was calculated for showing the cost of medicines 
acquired with clinical researches. It has been accepted that predicted budgets of 
reviewed files were spent for research. Similarly, it has been accepted that the num-
ber of patients was not changed during the studies. Thus, approved budgets could 
be accepted as drug investment of the approval year. For the calculation of drug 
costs, discounted reimbursement figures of Social Security Administration (SGK) 
for licenced products were used. If not licenced and imported via Turkish Chamber 
of Pharmacists, the prices of abroad drug list of SGK were used. Calculations were 
performed with the drug prices for the year 2013. Results: The average of drug cost 
savings per patient with participation to the clinical research and clinical research 
investment per patient were calculated as US$ 21.649 and US$ 4.879. It could be said 
that total budget of sponsored pharmaceutical researches was US$107 million and 
the government had a saving close to US$ 311.096.130 due to not reimbursing the 
cost of drugs of the patients who were included to the clinical researches in Turkey 
depending on the analysis. ConClusions: However study is based on assump-
tions, the findings are unique for the literature. The health policy makers can take 
account the study of the policy improvements about clinical trials in Turkey.
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objeCtives: With population of more than 1 Billion, Africa is the world’s second 
largest continent. The transition that African countries are undergoing is a real 
challenge for health care authorities. 24% of the global disease burden is accounted 
in Africa. The diseases that prevailed in the 60s and 70s have not completely disap-
peared, tuberculosis is still endemic as well as transmissible diseases like HIV/AIDS 
and Hepatitis still remained as a major problem while some others, such as cancers, 
cardiovascular and metabolic disorders are dramatically increasing, requiring the 
implementation of effective health care programs and leading to an increasing 
demand for drugs treatment. Methods: Inventory of the potential of Africa in 
clinical research. Results: In 2012, African Pharmaceutical market revenue was 
USD 18 Billion and expected to reach USD 30 Billion by 2016. Established countries in 
both Sub-Saharan and North African countries (South Africa, Nigeria, Cote d’Ivoire, 
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objeCtives: In 2011 the budget of the public payer in Poland, National Health Fund 
(NHF) amounted to 58.2 bln PLN. 47.3% of these funds was allocated to fund hospital 
treatment which is based on diagnosis-related groups (DRGs) but also includes 
innovative, expensive drugs (i. a. chemotherapy, orphan). The aim of the paper was 
to identify the existing correlation between hospital morbidity and the average unit 
cost of hospital treatment in various chronic diseases. Comparison of individual 
hospital costs of treatment different chronic diseases with varying degrees of sever-
ity, different course and level of incidence (from common to ultrarare) open the 
possibility of presenting the correlation between morbidity and unitary medical 
costs incurred by the NHF for the treatment of various indications. Methods: 
The analysis was prepared for 23 therapeutic areas, which were divided into 4 
categories (diseases: common, infectious, pediatric and rare /ultrarare), diversified 
both in terms of severity and morbidity. This choice gave a possibility of comparing 
a wide range of chronic diseases, which have a significant impact on quality of life 
and mortality. The analyzed material included hospital procedures and services 
indicated by the NHF in 2011. Results: Using the Pearson’s linear Correlation test, 
dependence between variables (the average cost of hospitalization and the number 
of patients) for 23 therapeutic areas was assessed. The results showed that the lower 
prevalence (fewer patients with the diagnosis) is connected with the higher average 
unit cost of treatment. ConClusions: In Poland, among all studied diseases the 
most expensive was the individual treatment of patients diagnosed with ultrarare 
diseases (i. a. Lysosomal storage diseases). Chronic ischemic heart disease, hyper-
tension and diabetes mellitus were associated with the largest number of annual 
hospitalizations and globally were the most cost-intensive for NHF. At the same 
time hypertension is associated with the lowest average unit cost of hospitalization 
among all studied diseases.
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objeCtives: Payers all need evidence of clinical effectiveness, reasonable cost, and 
safety. Although, patient-reported outcomes (PROs) are an important component of 
this evidence it is not always clear which PROs to use and reliance on an incorrect 
PRO can have negative consequences. The objective was to describe the factors 
determining which PROs are most likely to meet payer evidence needs. Methods: 
A structured discussion of factors influencing PRO choice was held between experts 
in late phase studies, evidence review, and economic modelling. These were then 
validated against a sample of published reimbursement decisions across multiple 
disease areas. Results: Focus of most questions is on whether to use a generic, 
disease-specific or novel measure. Disease specific PROs are very frequently of value 
in demonstrating clinical effectiveness and may be the standard clinical outcome. 
For example, migraine studies include pain assessment and headache frequency. To 
facilitate Payers’ decision making generic PROs such as EQ-5D and SF-36 are com-
monly used for assessing quality of life (QoL). However these instruments may not 
be reliable in disease areas characterised by focal impacts on patient wellbeing. For 
example, pain is only a small component of the SF-36 consequently changes in pain 
levels cannot be measured with great precision and the extreme effects of pain may 
be missed when generating estimates of utility. ConClusions: When choosing a 
PRO, it is important to consider the disease, treatment and payer reimbursement 
decision context. Disease specific QoL measures may be more sensitive than a 
generic tool but may also need mapping to a general QoL measure. Acceptance will 
be contingent on the existence of robust evidence either from published literature 
or additionally collected data. Reviews of previous HTA submissions and payer deci-
sions help identify requirements / standard practices in key markets and identify 
common criticisms or problems.
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objeCtives: Greece is under a very tough and strict memorandum enforced by 
the European Union that has designed and applied austerity measures in order 
to save Greek economy and minimizes its public debt. Also the Greek Heath care 
system should be improved, upgraded or redesigned from scratch in order to be 
more flexible and more efficient. The legislative intervention made by the European 
Union and the memorandum in Greek Heath Care system and the Pharmaceutical 
market constituted legislative framework for the Greek Heath Care and the 
Pharmaceutical sector. Methods: Data on total pharmaceutical expenditures 
from 2009-2011, some of them until 2012 were obtained from Hellenic Association 
of Pharmaceutical Companies. They were analyzed using basic statistical methods 
of observing. Results: In nearly all observed parameters was recorded their low-
ering. Total pharmaceutical expenditures per capita Δ x2009-2011= -20%, x2011= 5.073 
mil € , pharmaceutical expenditure as% of health expenditure Δ x2009-2011= -6,5%, 
x2011= 24,1%, pharmaceutical expenditure as % of GDP Δ x2009-2011= -11,1%, x2011= 
2,4%, private pharmaceutical expenditure Δ x2009-2011= -13%, x2011= 1.094 mil € , pri-
vate pharmaceutical expenditure per capita Δ x2009-2011= -13,5%, x2011= 96 € , public 
pharmaceutical expenditure Δ x2009-2012= -36,8%, x2012= 3.215 € , public pharmaceu-
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the treatment of asthma were not accepted due to comments about population 
and model input, lack of statistical calculations and size of the incremental effects. 
Ranibizumab’s results for age-related macular degeneration were not accepted 
because of a wrong comparator, lack of long term data, assumptions on risks and 
mortality, and uncertainties around health care costs and ICER sensitivity. Finally, 
ZiNL considered the appropriate use of alglucosidase alfa for Pompe’s disease 
to be unsubstantiated because of the population choice for the ICER calculation 
and the use of a higher dose than the registered dose which was not supported 
by scientific data. The outcome results of alglucosidase alfa for cost-effectiveness 
were accepted, however. ConClusions: Although at T= 0 ZiNL provided feedback 
regarding the design of the outcome research study, most of ZiNL’s comments were 
on the final methodology used. The outcome research studies were considered 
to be of mixed quality and the results could often not substantiate the claim of 
cost-effectiveness and appropriate use.
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objeCtives: In the UK, when a technology is recommended by the National 
Institute for Health and Care Excellence (NICE), the NHS is mandated to provide 
the funding to accommodate it within three months. Explicit in NICE’s approach 
to health technology assessment (HTA) is the assumption that the approval of a 
new, cost-increasing technology will result in the displacement of an existing, less 
cost-effective health care programme from elsewhere in the NHS. The objective 
of this study is to identify the actual opportunity costs of specific NICE decisions 
by documenting how in practice local commissioners in Wales accommodated 
financial shocks arising from technology appraisals (TAs). Methods: Interviews 
were conducted with Finance and Medical Directors from all seven Local Health 
Boards (LHBs) in NHS Wales. These interviews covered prioritisation processes, as 
well as methods of financing NICE TAs and other financial “shocks” at each LHB. 
We then undertook a systematic identification of themes and topics from the 
information recorded. Results: The financial impact of NICE TAs is generally 
planned for in advance and the majority of LHBs have contingency funds avail-
able for this purpose. Efficiency savings (defined as reductions in costs with no 
assumed reductions in quality) were a major source of funds for all cost pressures. 
Service displacements were not linkable to particular TAs and there appears to be 
a general lack of explicit prioritisation activities. The Welsh Government has, on 
occasion, acted as the funder of last resort. ConClusions: The assumption that 
newly recommended technologies will displace existing NHS services does not 
appear to hold true in practice. As the additional cost pressures represented by 
new NICE TAs are likely to be accommodated by greater efficiency and increased 
expenditure, the true opportunity cost of HTA decisions is extremely difficult to 
quantify and may even lie outside the NHS.
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objeCtives: Western countries health care systems face growing challenges deal-
ing with disability and death due to chronic diseases. Coordination of health care 
services has become unavoidable. Our objective was to identify the Integrated 
Health Services (IHS) in the major health care markets and understand the fund-
ing process. Methods: IHS provided in Europe, North America and Asia were 
identified through a literature review. Future perspectives were based on country 
policy and observed trends. Results: All studied countries developed IHS such 
as disease management, case management and telemonitoring services, with the 
United States (US) being the major market. However, levels of implementation, 
funding processes and stakeholders involved vary highly between different coun-
tries. Funding processes such as fee for services and capitation are widely used in 
all studied countries and Payment for performance (P4P), bundled payment and 
diagnosis-related group (DRG) for outpatient are in progress, used mainly in the 
US, and to a much lower extent in the United Kingdom (UK) and Germany. Multiple 
IHS exists in France, though inappropriate incentives hinder their development. In 
the US, under the Affordable Care Act, Accountable Care Organisations (ACOs) are 
testing a range of payment models (capitation, one-sided/two-sided shared sav-
ing fee-for-service, bundled/episode payments and P4P). ConClusions: IHS have 
become ubiquitous in all health organisations. All countries studied are expected to 
develop more IHS based on P4P schemes. The P4P of ACOs represents the ultimate 
gold mine for the development of paid health care services. Even if this concept is 
still in progress it will be leading this market. This will also change dramatically the 
way pharmaceutical companies will do business. Drugs will have to be integrated 
in a more complex selling process driven by medium to long term outcome impact. 
The management of confounding factors on outcomes is critical and represents 
the challenge for ACOs.
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objeCtives: The comprehensive implementation of telemedical applications still 
lags behind expectations in Germany. One of the main barriers to innovation is a 
lack of both a willingness to adapt and user’s acceptance. Processes of adoption 
and acceptance are characterized by a network of different factors which influ-
ence attitude and behavior which differ in severity depending on each user group. 
One key factor for accepting and adopting an innovation is the economic frame-
work. We therefore examined the influence of economic factors influencing the 
Senegal, Egypt, Morocco, Algeria and Tunisia) are contributing # 80% of the pharma 
market in Africa. Despite maintaining regional offices within Africa, many major 
Pharma and device manufacturers frequently overlook the continent when sponsor-
ing clinical studies. Cultural barriers, political upheaval and uneven infrastructure 
are certainly causes for the lack of interest. But Africa offers tremendous expertise 
and opportunity for drug and device companies looking for cost-effective study 
sites and appropriate patient drug market populations. Currently more than 45% 
of the whole continent’s clinical trials are being conducted in South Africa and 
hence the need for the next generation clinical trial destination for a drug and 
device manufacturers. These companies can also consider technology transfer by 
partnering with local drug manufacturers and research centers to diversify their 
business portfolio. ConClusions: Africa presents real opportunities that should 
encourage many pharmaceutical companies to really engage in innovative clinical 
research programs in a win-win approach.
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objeCtives: Although, whether biologically active supplements (BAS) are medi-
cines or not is still debatable, BAS keep making their way to the customer basically 
through pharmacies. A worldwide tendency toward “greener” choices when pur-
chasing health status modifiers (HSM) is well documented. Current endeavor studies 
the pharmaceutical market situation (PMS) in Armenia (2009 to 2013) in regard to 
growth trends both in US dollars turnover (USDT) and number of packs sold (NPS) of 
BAS versus medicines, stratified by five leading diseases (LD). Methods: Statistical 
data on morbidity and mortality from the MOH RA were used to identify the leading 
five disease groups in newly identified cases. Further, statistical data on pharmaceu-
tical market from “Pharmexpert” Marketing Research Centre (analysis of wholesale 
sales volumes to the retail drug stores) were investigated to identify growth rate 
(GR) trends of interest. Results: A PMS analysis has shown 11.92% and 6.65% of 
GR (medicines and BAS combined) in USDT and NPS respectively. For medicines 
alone the results were: 11.56% and 6.23% GR in USDT and NPS respectively. As for 
BAS, USDT and NPS, the figures were 21.48% and 15.36% of GR respectively. A further 
stratification by five LM has shown the highest GR in medicines used for treatment 
of Uro-Genital diseases (13.24% and 10.01% for USDT and NPS respectively), whereas 
in BAS the highest GR was in the Cardio-Vascular group (63.84% and 92.82% for USDT 
and NPS respectively). ConClusions: The results of the study go in line with the 
worldwide trends in shifting whenever possible, from medicines to using HSM of 
natural origin, of which BAS are a major part. The study does not claim to identify 
the underlying compound factors influencing such a tendency. However, the reality 
at had compels for studying the levels of BAS administration and use literacy among 
both HSM prescribers and consumers.
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objeCtives: This study seeks to evaluate the incremental benefit scores granted 
to new medicines under the 2011 AMNOG reform in Germany, and if there is a 
correlation between that score and the extent of price reduction after negotiation 
with the statutory health insurance fund. Methods: Resolutions issued by the 
G-BA related to all drugs which achieved the early benefit assessment process 
between January 2011 and June 2014 were reviewed to determine whether the 
drugs were deemed to bring an added benefit. Under AMNOG, an added therapeu-
tic benefit score is granted to medicines according to 6 categories (major, consid-
erable, minor, non-quantifiable, no or less added benefit versus the comparator). 
As part of the study, IHS created an overall quantitative innovation score for each 
product, based on any and all qualitative ratings granted by the G-BA in each 
patient subgroup. The score ranged from 0 (no added benefit proven) to 4 (major 
added benefit) and was weighted against each patient population. An average price 
reduction per innovation score range was then calculated. Results: Out of the 76 
drugs assessed in the study, a total of 44 were deemed to bring an added benefit 
over the appropriate comparator by the G-BA, of which 34 had achieved price nego-
tiation as of end of May 2014. These ratings translated into an average innovation 
score of 1.77, and were subject to price cuts averaging 21.7%. ConClusions: Our 
analysis highlights that innovative medicines can be subject to significant price 
cuts in Germany. No correlation between the innovation score and subsequent 
price cuts could be derived, as many other factors, including the initial price dif-
ference between the new medicine and the comparator, enter into account as 
part of the price negotiations.
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objeCtives: If the cost-effectiveness and appropriate use of a drug in the 
Netherlands cannot yet be determined during the initial reimbursement assess-
ment (T= 0), this will be done at the re-evaluation 4 years later (T= 4) using RWD. 
Outcome research is an essential part of the re-evaluation of conditionally reim-
bursed drugs. The objective was to assess the reasons for accepting or rejecting 
outcome research results to confirm cost-effectiveness and appropriate use of 
a drug at T= 4. Methods: The website of Zorginstituut Nederland (ZiNL) was 
searched for re-evaluations of drugs published between January 2006 and May 
2014. ZiNL’s assessments of the outcome research were compared. Results: ZiNL 
published the outcome research results for four drugs. The outcome research 
results for agalsidase alfa & beta were accepted for demonstrating cost-effective-
ness and appropriate use in Fabry’s disease. The T= 4 results for omalizumab for 
